<DOC>
	<DOC>NCT01306409</DOC>
	<brief_summary>The purpose of this study is to gain information on reticulocyte neocytolysis in patients treated with ESA with regard to different types of ESA.</brief_summary>
	<brief_title>Neocytolysis in the Treatment of Renal Anemia With Erythropoieses Stimulating Agents (ESA)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>signed informed consent age &gt; 18 years, dialysis dependent chronic renal failure hemodialysis three times a week Kt/V &gt; 1,2 od URR &gt; 65% hemoglobin between 11 and 13 g/dl within the last 2 months hemoglobin change +/ 1g/dl within the last 4 weeks ESA for at least 8 weeks Ferritin &gt; 300 ng/ml and Tsat &gt; 25% Significant bleeding in the last 8 weeks blood transfusion within the last 8 weeks hemoglobin disorder hemolysis Malignant disease Significant inflammation Acute infection CRP &gt; 30 mg/l Temporary vascular dialysis access Vitamin B12 deficiency Folic acid deficiency Not controlled hyperparathyroidism Not controlled hypertension Epilepsia within thze last 6 months Thrombocyte count &gt; 500 x 10^9 /l</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>anemia</keyword>
	<keyword>kidney disease</keyword>
</DOC>